Stockscreener 앱 받기
0.9779
1.02%
-0.0101
전일 마감가:
$0.988
열려 있는:
$0.9595
하루 거래량:
451.38K
Relative Volume:
1.77
시가총액:
$59.23M
수익:
-
순이익/손실:
$-64.86M
주가수익비율:
-0.8731
EPS:
-1.12
순현금흐름:
$-55.66M
1주 성능:
-17.82%
1개월 성능:
-19.18%
6개월 성능:
-58.74%
1년 성능:
-74.53%
1일 변동 폭
$0.902
$0.9869
1주일 범위
$0.902
$1.18
52주 변동 폭
$0.902
$4.00
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
명칭
Acumen Pharmaceuticals Inc
전화
925-368-8508
주소
427 PARK ST., CHARLOTTESVILLE
ABOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
0.9779 | 59.23M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-26 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-20 | 재개 | BofA Securities | Buy |
| 2023-05-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-07-15 | 개시 | BTIG Research | Buy |
| 2022-06-30 | 개시 | H.C. Wainwright | Buy |
| 2022-01-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-07-26 | 개시 | BofA Securities | Neutral |
| 2021-07-26 | 개시 | Credit Suisse | Outperform |
| 2021-07-26 | 개시 | Stifel | Buy |
| 2021-07-26 | 개시 | UBS | Buy |
모두보기
Acumen Pharmaceuticals Inc 주식(ABOS)의 최신 뉴스
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - The Manila Times
Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation - Stock Titan
Charles Schwab Investment Management Inc. Acquires 18,004 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
What is HC Wainwright’s Forecast for ABOS FY2029 Earnings? - Defense World
FY2029 Earnings Forecast for ABOS Issued By HC Wainwright - The AM Reporter
UBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00 - Defense World
Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline - MSN
HC Wainwright Has Lowered Expectations for Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Cut to $11.00 by Analysts at HC Wainwright - The AM Reporter
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
Bank of America Securities Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
UBS Cuts Price Target on Acumen Pharmaceuticals to $4 From $6, Keeps Buy Rating - MarketScreener
Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Acumen Pharmaceuticals Advances Alzheimer’s Treatment Efforts - TipRanks
Earnings call transcript: Acumen Pharmaceuticals Q4 2024 focuses on Alzheimer’s innovations - Investing.com
Acumen Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights - The Manila Times
Acumen's $231M War Chest Powers Breakthrough Alzheimer's Drug Development - Stock Titan
Acumen Pharmaceuticals completes Phase 2 trial enrollment By Investing.com - Investing.com South Africa
Preview: Acumen Pharmaceuticals's Earnings - Benzinga
Acumen Pharmaceuticals completes Phase 2 trial enrollment - Investing.com
Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer'S Disease - Marketscreener.com
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease - TradingView
Breakthrough Alzheimer's Treatment Advances: Phase 2 Trial Fills Ahead of Schedule - Stock Titan
Acumen Pharmaceuticals Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - The Manila Times
Acumen Pharmaceuticals To Report Fourth Quarter And Year-End 2024 Financial Results On March 27, 2025 - MarketScreener
Acumen Pharmaceuticals to Reveal Full Year Performance: Key Updates on Alzheimer's Treatment Progress - StockTitan
Acumen reports positive results for Alzheimer’s drug sabirnetug By Investing.com - Investing.com South Africa
Central Nervous System (CNS) Biomarkers Market Report Analysis - openPR
Acumen Pharma Reports Positive Topline Data For Sabirnetug From Phase 1 Study - Nasdaq
Acumen reports positive results for Alzheimer’s drug sabirnetug - Investing.com
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers - The Manila Times
Breakthrough in Alzheimer's Treatment: Acumen's New Injectable Drug Shows Promise in Phase 1 - StockTitan
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report - GlobeNewswire
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report - GlobeNewswire Inc.
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s - Yahoo Finance
Acumen Pharmaceuticals at UBS Virtual CNS Day: Alzheimer’s Treatment Focus - Investing.com UK
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Tuesday - Defense World
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting - The Manila Times
Acumen Pharmaceuticals, Inc. to Present Research on Sabirnetug for Alzheimer's Disease at International Conferences in April 2025 - Nasdaq
Groundbreaking Alzheimer's Drug Development: Acumen Reveals Latest Research at Two Leading Conferences - StockTitan
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Shares Sold by Rhumbline Advisers - Defense World
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Alzheimer's Drug Developer Acumen Sets March Investor Presentations - StockTitan
Cancer Immunotherapy Market Detailed In New Research Report 2025 | Gilead Sciences, Inc., Johnson & Johnson - openPR
Reviewing Acumen Pharmaceuticals (NASDAQ:ABOS) & Eloxx Pharmaceuticals (NASDAQ:ELOX) - Armenian Reporter
ABOS stock touches 52-week low at $1.28 amid market challenges - Investing.com India
ABOS stock touches 52-week low at $1.28 amid market challenges By Investing.com - Investing.com South Africa
Acumen Pharmaceuticals Inc (ABOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acumen Pharmaceuticals Inc 주식 (ABOS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
3.01%
자본화:
|
볼륨(24시간):